Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial

✍ Scribed by Paul Richardson; Rudolf Schlag; Nuriet Khuageva; Meletios Dimopoulos; Ofer Shpilberg; Martin Kropff; Marie-Christiane Vekemans; Maria Teresa Petrucci; Viktor Rossiev; Jian Hou; Tadeusz Robak; Maria-Victoria Mateos; Kenneth Anderson; Dixie-Lee Esseltine; Andrew Cakana; Kevin Liu; William Deraedt; Helgi van de Velde; Jesús F. San Miguel

• Book ID: 108677151
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 184 KB
• Volume: 153
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2011.08569.x